Atopic dermatitis

Atopic dermatitis

Atopic dermatitis (AD) often begins in infancy and affects up to 25% of children. Topical steroids are often the treatment of choice for inflammatory skin diseases like AD, but they come with unwanted side effects. Current non-steroidal drugs typically use a single or dual-target approach, resulting in suboptimal efficacy. Itch Is the most prevalent, severe, and burdensome symptom of AD.
DB-007-4 targets a wide array of pathways overactive in AD, and in repeated trials using well-established animal models that mimic the human disease, DB-007-4 exhibited significant inhibitory effects in both disease score and itch. DB-007-4 is well-tolerated by skin.